[go: up one dir, main page]

AU2002336433A1 - Tricyclic compounds useful for modulating lxr - Google Patents

Tricyclic compounds useful for modulating lxr

Info

Publication number
AU2002336433A1
AU2002336433A1 AU2002336433A AU2002336433A AU2002336433A1 AU 2002336433 A1 AU2002336433 A1 AU 2002336433A1 AU 2002336433 A AU2002336433 A AU 2002336433A AU 2002336433 A AU2002336433 A AU 2002336433A AU 2002336433 A1 AU2002336433 A1 AU 2002336433A1
Authority
AU
Australia
Prior art keywords
compounds useful
tricyclic compounds
modulating lxr
lxr
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002336433A
Other languages
English (en)
Inventor
Thomas Patrick Burris
Guoqing Cao
George Joseph Cullinan
Patrick Irving Eacho
Jefferson Ray Mccowan
Kuo-Long Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002336433A1 publication Critical patent/AU2002336433A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002336433A 2001-10-08 2002-09-30 Tricyclic compounds useful for modulating lxr Abandoned AU2002336433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32764401P 2001-10-08 2001-10-08
US60/327,644 2001-10-08
PCT/US2002/028147 WO2003031408A2 (fr) 2001-10-08 2002-09-30 Composes tricycliques utiles pour moduler lxr

Publications (1)

Publication Number Publication Date
AU2002336433A1 true AU2002336433A1 (en) 2003-04-22

Family

ID=23277404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336433A Abandoned AU2002336433A1 (en) 2001-10-08 2002-09-30 Tricyclic compounds useful for modulating lxr

Country Status (2)

Country Link
AU (1) AU2002336433A1 (fr)
WO (1) WO2003031408A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072046A2 (fr) * 2003-02-12 2004-08-26 Carex S.A. Modulation de l'activite des recepteurs nucleaires
SV2005001973A (es) * 2003-12-12 2005-11-04 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
EP2348857B1 (fr) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
MY159058A (en) 2011-02-25 2016-12-15 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
EP2880028B1 (fr) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Composés tricycliques anti-diabétiques
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015106164A1 (fr) 2014-01-10 2015-07-16 Rgenix, Inc. Agonistes du récepteur x du foie et leurs utilisations
CA3010883A1 (fr) 2016-01-11 2017-07-20 The Rockefeller University Methodes pour le traitement de troubles associes a des cellules suppressives derivees de cellules myeloides
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
CN111303017B (zh) * 2019-08-28 2022-11-11 上海中医药大学 一类含9,10-二氢菲骨架的化合物及其制备方法和用途
WO2021119397A1 (fr) 2019-12-13 2021-06-17 Rgenix, Inc. Sels métalliques et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
AU4701299A (en) * 1998-06-23 2000-01-10 Stuart R. Adler Therapeutic applications of estrogenic carboxylic acids
CA2392568A1 (fr) * 1999-12-13 2001-06-14 Merck & Co., Inc. Procede de prevention et/ou de traitement de l'atherosclerose

Also Published As

Publication number Publication date
WO2003031408A3 (fr) 2003-08-14
WO2003031408A2 (fr) 2003-04-17

Similar Documents

Publication Publication Date Title
AU2002323787A1 (en) Spiro compounds
AU2002349297A1 (en) Statin-like compounds
AUPS137402A0 (en) Novel tricyclic compounds
AU2002336433A1 (en) Tricyclic compounds useful for modulating lxr
AU2001292518A1 (en) Novel compounds
AU2000235960A1 (en) Lxr modulators
AU2002359165A1 (en) Novel compounds
AU2001239765A1 (en) Novel compounds
AU2001246998A1 (en) Novel compounds
AUPR878201A0 (en) New compounds
AU2001253362A1 (en) Novel compounds
AU2001288110A1 (en) Spiro compounds
AU2002231077A1 (en) Novel compounds
AU2001256964A1 (en) Novel compounds
AU2001252575A1 (en) Novel tricyclic compounds
AU2001230689A1 (en) Novel compounds
AU2002221923A1 (en) Novel compounds
AU2002216060A1 (en) Novel compounds
AU2001276890A1 (en) Novel compounds
AU2001258760A1 (en) Novel thiophenamide compounds
AU2001252573A1 (en) Novel substituted tricyclic compounds
AUPR920301A0 (en) Neurologically-active compounds
AU2001237533A1 (en) Novel p-gp-inhibiting compounds
AU2001232568A1 (en) Novel compounds
AU2001274891A1 (en) Tricyclic compounds as mrp1-inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase